Biohaven Pharma to continue late-stage study of Alzheimer's treatment [Reuters]
Biohaven Ltd. Common Shares (BHVN)
Last biohaven ltd. common shares earnings: 2/25 04:45 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.biohavenpharma.com
Company Research
Source: Reuters
Biohaven Pharma to continue late-stage study of Alzheimer's treatment (Reuters) - Biohaven Pharmaceutical said on Friday it would continue with a late-stage study of its experimental Alzheimer’s treatment on the recommendation of an independent data-monitoring committee based on an interim analysis of results. In order to pass the analysis, the treatment troriluzole had to demonstrate numerically greater benefit over placebo on at least one of two pre-specified criteria: a measure of cognitive function or hippocampal volume assessed by magnetic resonance imaging. The study is being led by the Alzheimer’s Disease Cooperative Study (ADCS) at the University of California San Diego School of Medicine. Alzheimer’s is a progressive neurodegenerative disorder that causes brain cells to waste away and die and accounts for 60%-80% of dementia cases.
Show less
Read more
Impact Snapshot
Event Time:
BHVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BHVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BHVN alerts
High impacting Biohaven Ltd. Common Shares news events
Weekly update
A roundup of the hottest topics
BHVN
News
- Biohaven Ltd. (NYSE: BHVN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Biohaven Ltd. (NYSE: BHVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.MarketBeat
- Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates [Yahoo! Finance]Yahoo! Finance
- Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program UpdatesPR Newswire
- Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
BHVN
Earnings
- 11/12/24 - Miss
BHVN
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form 8-K
- 11/12/24 - Form 10-Q
- BHVN's page on the SEC website